secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2024-06-28T23:59:59+00:00
Accession:  0001104659-24-076382
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute releases Phase 2 topline results for RZ402 in DME; no specifics in filing
--------------------------------------------------------------------------------

- Topline results from Phase 2 study of RZ402 in diabetic macular edema (DME) disclosed via website and SEC filing on June 28, 2024.
- Presentation originally provided during May 21, 2024 investor webcast; appendix added on June 28, 2024.
- Actual efficacy or safety data (e.g., p-values, responder rates) are not visible in the available 8-K or exhibit text.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465924076382/0001104659-24-076382-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465924076382/tm2418270d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-076382

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer